Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Argenica Therapeutics Ltd ( (AU:AGN) ) just unveiled an update.
Argenica Therapeutics Limited announced the successful passage of all resolutions at its Annual General Meeting held on November 12, 2025. The approval of resolutions, including the adoption of the remuneration report, re-election of a director, and approval of a 10% placement capacity, reflects strong shareholder support and positions the company for continued strategic growth.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a company operating in the biotechnology industry, focusing on the development of therapeutic products. The company is listed on the Australian Securities Exchange under the ticker AGN and is based in Perth, Australia.
Average Trading Volume: 586,727
Technical Sentiment Signal: Sell
Find detailed analytics on AGN stock on TipRanks’ Stock Analysis page.